Other Information.
+Added: Trading Arrangements
+Added: During the Company’s last fiscal quarter, one of the Company’s directors adopted a written plan for the sale of the Company’s common stock set forth in the table below.
+Added: Type of Trading Arrangement
+Added: Name and Position Action Adoption
+Added: Date Rule 10b5-1* Non-
+Added: Rule 10b5-1** Total Shares of Common Stock to be Sold Expiration Date
+Added: Deborah Messemer , Director
+Added: Adoption August 30, 2024 X ― 61,529 June 30, 2025
+Added: * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
+Added: ** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.
+Added: Table o f Contents
Description of document
8 unchanged sentences
333-227333), filed with the SEC on October 2, 2018).
−Removed: Share Exchange Agreement, dated May 24, 2024, by and among Allogene Overland Biopharm (CY) Limited, Overland Pharmaceutic als (CY) Inc.
−Removed: a nd Allogene Therapeutics Inc.
−Removed: Amended and Restated Shareholders' Agreement , dated May 24, 2024, by and among Allogene Overland Biopharm (CY) L imited, Allogene Therapeut ics Inc.
−Removed: and HH BioPharma Holdings Ltd.
−Removed: Firs t Amendment to the License Agreement , dated May 24, 20 24, by and between Allogene Therapeutics Inc .
−Removed: and Allogene Overland BioPharm (PRC) Co., Limited.
−Removed: A mendment and Settlement Agreement , dated May 10, 2024, by and between Les Laborato ires Servier, Institu t de Reche r ches Internationales Servier and Allogene Therapeutics, Inc.
−Removed: 10.5+ Securities Purchase Agreement by and among the Company and the Purchasers named therein, dated May 13, 2024 (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No.
−Removed: 001-38693), filed with the SEC on May 14, 2024)
−Removed: A mendment No.
−Removed: 1 to Amended and Restated Collaboration and License Agreement , dated May 17, 2024, by and between Allogene Therapeutics, Inc.
−Removed: and Notch Thera peutics (Canada) Inc.
−Removed: Amendment No.
−Removed: 1 to Strategic Collaboration Agreement , dated April 4 , 2024, by and between Allogene Therapeutics, Inc.
−Removed: and Foresight Di agnostics, Inc.
31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
9 unchanged sentences
104 The cover page from the Company’s Quarterly Report on Form 10-Q has been formatted in Inline XBRL.
−Removed: + Indicates management contract or compensatory plan.
−Removed: * Certain portions of this exhibit (indicated by “[***]”) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both not material and is the type of information that the Registrant treats as private or confidential.
−Removed: ‡ Schedules and Exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K.
+Added: Table o f Contents
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: August 7, 2024 By:
+Added: November 7, 2024 By:
/s/ David Chang
2 unchanged sentences
(Principal Executive Officer)
−Removed: August 7, 2024 By:
+Added: November 7, 2024 By:
/s/ Geoffrey Parker
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.